Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 15, Issue 4, 1995, Pages 441-445

  Bergmark, C ^a   Wu, R ^a   De Faire, U ^a   Lefvert, A K ^a   Swedenborg, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

antibodies; lipoproteins; oxidation; premature atherosclerosis; risk factors

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; AUTOANTIBODY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY OBSTRUCTION; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HUMAN; HYPERTENSION; KIDNEY ARTERY STENOSIS; LEG ISCHEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OXIDATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0028923681     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.15.4.441     Document Type: Article

References (34)

1. Aviram M. Modified forms of low density lipoprotein and atherosclerosis. Atherosclerosis. 1993;98:1-9.
2. Steinberg D. Modified forms of low-density lipoprotein and atherosclerosis. J Intern Med. 1993;233:227-232.
3. Rosenfeld ME, Palinski W, Ylä-Herttuala S, Butler S, Witztum JL. Distribution of oxidation-specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 1990;10:336-349.
4. Liu KT, Cuddy E, Pierce GN. Oxidative status of lipoproteins in coronary disease patients. Am Heart J. 1992;123:285-290.
5. Regnström J, Nilsson J, Tornvall P, Landou C, Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet. 1992;339:1183-1186.
6. Freyschuss A, Stiko-Rahm A, Swedenborg J, Henriksson P, Björkhem I, Berglund L, Nilsson J. Antioxidant treatment inhibits the development of intimal thickening after balloon injury of the aorta in hypercholesterolemic rabbits. J Clin Invest. 1993;91: 1282-1288.
7. Björkhem I, Henriksson-Freyschuss A, Breuer O, Diczfalusy U, Berglund L, Henriksson P. The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler Thromb. 1991;11:966-972.
8. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med. 1992;13:341-390.
9. Boyd HC, Gown AM, Wolfbauer G, Chait A. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol. 1989;135:815.
10. Zawadzki Z, Milne RW, Marcel YL. An immunochemical marker of low density lipoprotein oxidation. J Lipid Res. 1989;30:885-891.
11. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5-15.
12. Khoo JC, Miller E, Pio F, Steinberg D, Witztum JL. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler Thromb. 1992;12:1258-1266.
13. Orekhov AN, Tertov W, Kabakov AE, Adamova IY, Pokrosky SN, Smirnov VN. Autoantibodies against modified low density lipoprotein: nonlipid factor of blood plasma that stimulates foam cell formation. Arterioscler Thromb. 1991;11:316-326.
14. Ylä-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 1994;14:32-40.
15. Morganelli PM, Kitzmiller TJ, Hemmer R, Fanger M. Redirected targeting of LDL to human monocyte Fc-gamma receptors with bispecific antibodies. Arterioscler Thromb. 1992;12:1131-1138.
16. Stemme S, Hansson GK. Immune mechanisms in atherogenesis. Ann Med. 1994;26:141-146.
17. Lopes-Virella MF, Virella G. Immune mechanisms of atherosclerosis in diabetes mellitus. Diabetes. 1992;41(suppl 2):86-91.
18. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-1353.
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193: 265-275.
20. Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med. 1990;114:383-387.
21. Steinbrecher UP, Lougheed M. Scavenger receptor-independent stimulation of cholesterol esterification in macrophages by low density lipoprotein extracted from human aortic intima. Arterioscler Thromb. 1992;12:608-625.
22. Palinski W, Ylä-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum L. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis. 1990;10: 325-335.
23. Parthasarathy S, Fong LG, Quinn MT, Steinberg D. Oxidative modification of LDL: comparison between cell-mediated and copper-mediated modification. Eur Heart J. 1990;11(suppl E):83-87.
24. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssönen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883-887.
25. Virella G, Virella I, Leman RB, Pryor MB, Lopes-Virella MF. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res. 1993;23:95-101.
26. Schumacher M, Eber B, Tatzber F, Kaufmann P, Esterbauer H, Klein W. LDL oxidation and coronary athuascluoris. Lancet. 1992; 340:123. Letter.
27. Zieden B, Mölgaard J, Olsson AG. Low-density lipoprotein oxidation and coronary atherosclerosis. Lancet. 1992;340:727-728. Letter.
28. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Paulosuo T. Crossreaction between antibodies to oxidised lowdensity lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993;341:923-925.
29. Martin-Nizard F, Houssaini H, Lestavel-Delatte S, Duriez P, Fruchart J. Modified low density lipoproteins activate human macrophages to secrete immunoreactive endothelin. FEBS Lett. 1991; 293:127-130.
30. Mangin E Jr, Kugiyama K, Nguy JH, Kerns SA, Henry PD. Effects of lysolipids and oxidatively modified low density lipoprotein on endothelium-dependent relaxation of rabbit aorta. Circ Res. 1993; 72:161-166.
31. Weisser B, Locher R, Mengden T, Sachinidis A, Vetter W. Oxidized low-density lipoproteins in atherogenesis: possible mechanisms of action. J Cardiovasc Pharmacol. 1992;19(suppl 2):4-7.
32. Maggi E, Marchesi E, Ravetta V, Falaschi F, Finardi G, Bellomo G. Low-density lipoprotein oxidation in essential hypertension. J Hypertens. 1993;11:1103-1111.
33. Harats D, Ben-Naim M, Dabach Y, Hollander G, Stein O, Stein Y. Cigarette smoking renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages. Atherosclerosis. 1989;79:245-252.
34. Frei B, Forte TM, Ames BN, Cross CE. Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Biochem J. 1991; 277:133-138.